CF
KROS icon

Corebridge Financial’s Keros Therapeutics KROS Stock Holding History

Corebridge Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,212
Closed -$165K – 1466
2025
Q1 		$165K Buy
16,212
+972
+6% +$11.3K ﹤0.01% 2179
2024
Q4 		$241K Sell
15,240
-515
-3% -$26.8K ﹤0.01% 2072
2024
Q3 		$915K Sell
15,755
-97
-0.6% -$4.79K ﹤0.01% 1401
2024
Q2 		$724K Buy
+15,852
New +$852K ﹤0.01% 1501

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Corebridge Financial's KROS Position: Q2 2025 in Review

Corebridge Financial sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 16,212 shares — an estimated $165K sold.

Corebridge Financial first reported a position in KROS in Q2 2024 and held it in 4 quarters. The position peaked at $915K in Q3 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Corebridge Financial reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 16,212 Keros Therapeutics shares in Q2 2025, an estimated $165K.
  • Corebridge Financial first reported a position in Keros Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Keros Therapeutics position peaked at $915K in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.